NASDAQ : CLLS
Cellectis S.A. — Key statistics
Healthcare · Biotechnology · France
Last price 1.08 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 84.26M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 84.26M |
| Enterprise Value | -121,942 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 72.70M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 18.71% |
| Float | 48.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.32 |
| Forward PS | 0.87 |
| PB Ratio | 2.05 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.37 |
| Quick Ratio | 1.34 |
| Debt / Equity | 1.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.18 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -94.54% |
| Return on Assets (ROA) | -11.67% |
| Return on Invested Capital (ROIC) | -23.43% |
| Return on Capital Employed (ROCE) | -43.80% |
| Weighted Average Cost of Capital (WACC) | 14.26% |
| Revenue Per Employee | $278,703 |
| Profits Per Employee | -$285,214 |
| Employee Count | 229 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -351,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.91 |
| 52-Week Price Change | -70.25% |
| 50-Day Moving Average | 1.89 |
| 200-Day Moving Average | 3.07 |
| Relative Strength Index (RSI) | 37.82 |
| Average Volume (20 Days) | 108,389 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 320,614 |
| Short Previous Month | 351,327 |
| Short % of Shares Out | 0.58% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 63.82M |
| Gross Profit | 63.82M |
| Operating Income | -58.00M |
| Pretax Income | -65.67M |
| Net Income | -65.31M |
| EBITDA | -46.68M |
| EBIT | -58.00M |
| Loss Per Share | -$0.64 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 166.69M |
| Total Debt | 80.35M |
| Net Cash | 86.34M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 41.07M |
| Book Value Per Share | 0.56 |
| Working Capital | 49.46M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -41.63M |
| Capital Expenditures | -2.18M |
| Depreciation & Amortization | 11.32M |
| Net Borrowing | -16.36M |
| Free Cash Flow | -43.80M |
| FCF Per Share | -$0.60 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -90.87% |
| Pretax Margin | -102.89% |
| Profit Margin | -102.34% |
| EBITDA Margin | -73.14% |
| EBIT Margin | -90.87% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -58.84% |
| FCF Yield | -51.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.83 |
| Price Target Difference | 347.22% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -20.99% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.16 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |